- Home
- ANSC vs MRVI Comparison
ANSC vs MRVI Comparison
Compare ANSC & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSC
- MRVI
- Stock Information
- Founded
- ANSC 2021
- MRVI 2014
- Country
- ANSC United States
- MRVI United States
- Employees
- ANSC N/A
- MRVI N/A
- Industry
- ANSC
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ANSC
- MRVI Health Care
- Exchange
- ANSC Nasdaq
- MRVI Nasdaq
- Market Cap
- ANSC 466.6M
- MRVI 376.2M
- IPO Year
- ANSC 2023
- MRVI 2020
- Fundamental
- Price
- ANSC N/A
- MRVI $3.36
- Analyst Decision
- ANSC
- MRVI Hold
- Analyst Count
- ANSC 0
- MRVI 9
- Target Price
- ANSC N/A
- MRVI $4.54
- AVG Volume (30 Days)
- ANSC 5.7K
- MRVI 1.5M
- Earning Date
- ANSC 01-01-0001
- MRVI 11-06-2025
- Dividend Yield
- ANSC N/A
- MRVI N/A
- EPS Growth
- ANSC N/A
- MRVI N/A
- EPS
- ANSC 0.14
- MRVI N/A
- Revenue
- ANSC N/A
- MRVI $219,830,000.00
- Revenue This Year
- ANSC N/A
- MRVI N/A
- Revenue Next Year
- ANSC N/A
- MRVI $7.23
- P/E Ratio
- ANSC $80.51
- MRVI N/A
- Revenue Growth
- ANSC N/A
- MRVI N/A
- 52 Week Low
- ANSC $10.36
- MRVI $1.67
- 52 Week High
- ANSC $11.06
- MRVI $8.54
- Technical
- Relative Strength Index (RSI)
- ANSC N/A
- MRVI 67.37
- Support Level
- ANSC N/A
- MRVI $2.94
- Resistance Level
- ANSC N/A
- MRVI $3.40
- Average True Range (ATR)
- ANSC 0.00
- MRVI 0.20
- MACD
- ANSC 0.00
- MRVI 0.05
- Stochastic Oscillator
- ANSC 0.00
- MRVI 87.65
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.